Previous close | 0.4000 |
Open | 0.8500 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 105.00 |
Expiry date | 2024-05-17 |
Day's range | 0.4000 - 0.8500 |
Contract range | N/A |
Volume | |
Open interest | 34 |
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in CAH. These data, along with several additional posters were presented a
Neurocrine Biosciences is making good on its promise to diversify from Ingrezza. Meanwhile, the biotech stock is angling for a record.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline characteristics for adults with congenital adrenal hyperplasia (CAH) enrolled in the study, as well as data from a comprehensive literature review assessing the impact of supraphysiologic glucocorticoid (GC) doses on psychiatric disorders and cognition in patients with CAH.